Q-omics provides the consensus-scored PRR13P4 profile across patient tissues and cancer cell-line models. PRR13P4 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ESCA. Among the 18 cancer types available for tumor–normal comparison, PRR13P4 is differentially expressed in 4, with the highest sampling consensus in LIHC. Additionally, PRR13P4 RNA expression shows 5,243 significant pathway-activity associations, with the highest sampling consensus in UCEC. Together, these results highlight ESCA, LIHC, and UCEC as cancer lineages where PRR13P4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRR13P4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRR13P4 survival associations across molecular data types. PRR13P4 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRR13P4 RNA expression–survival associations across cancer types. High PRR13P4 expression shows unfavorable associations in ESCA, KICH, THYM and TGCT, but favorable associations in COAD and UCEC. The ESCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .009). Together, the overview and detailed table identify ESCA as the clearest survival context for PRR13P4 RNA expression.
This table summarizes PRR13P4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for PRR13P4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRR13P4 shows lower tumor expression in THCA and higher tumor expression in LIHC, LUSC and BRCA. The LIHC box plot shows higher PRR13P4 RNA expression in tumor versus normal tissue (log2 FC = +0.065, t-test p = .012).
This table shows molecular features associated with PRR13P4 in patient tissues and cancer cell lines. In patient samples, PRR13P4 shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set.
